Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03101475
Title Synergism of Immunomodulation and Tumor Ablation (ILOC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Organisation for Research and Treatment of Cancer - EORTC
Indications

colorectal cancer

Therapies

Durvalumab + Tremelimumab

Age Groups: senior | adult
Covered Countries FRA | DEU | AUT

Facility Status City State Zip Country Details
Medical University Vienna - General Hospital AKH Vienna Austria Details
Institut Bergonie Bordeaux France Details
Universitaetsklinikum Carl Gustav Carus Dresden Germany Details
Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden Leipzig Germany Details
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis Amsterdam Netherlands Details
Radboud University Medical Center Nijmegen Nijmegen Netherlands Details
Karolinska University Hospital - Karolinska Institutet - Danderyds Hospital Stockholm Sweden Details
Inselspital Bern Switzerland Details
Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie Geneva Switzerland Details
UniversitaetsSpital Zurich Zürich Switzerland Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field